US 11,840,692 B2
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
Brian Bettencourt, Groton, MA (US); William Querbes, Boston, MA (US); Kevin Fitzgerald, Brookline, MA (US); Maria Frank-Kamenetsky, Brookline, MA (US); Stuart Milstein, Arlington, MA (US); and Svetlana Shulga Morskaya, Sudbury, MA (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Nov. 22, 2021, as Appl. No. 17/531,919.
Application 17/531,919 is a continuation of application No. 17/089,854, filed on Nov. 5, 2020, granted, now 11,332,743.
Application 17/089,854 is a continuation of application No. 16/411,261, filed on May 14, 2019, granted, now 10,934,545, issued on Mar. 2, 2021.
Application 16/411,261 is a continuation of application No. 15/683,999, filed on Aug. 23, 2017, granted, now 10,337,010, issued on Jul. 2, 2019.
Application 15/683,999 is a continuation of application No. 15/068,912, filed on Mar. 14, 2016, granted, now 9,771,591, issued on Sep. 26, 2017.
Application 15/068,912 is a continuation of application No. 14/132,999, filed on Dec. 18, 2013, granted, now 9,322,018, issued on Apr. 26, 2016.
Application 14/132,999 is a continuation of application No. PCT/US2012/043378, filed on Jun. 20, 2012.
Claims priority of provisional application 61/638,288, filed on Apr. 25, 2012.
Claims priority of provisional application 61/499,620, filed on Jun. 21, 2011.
Prior Publication US 2022/0073928 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 31/7105 (2006.01); C12Q 1/68 (2018.01)
CPC C12N 15/1136 (2013.01) [A61K 31/713 (2013.01); A61K 31/7105 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3515 (2013.01)] 29 Claims
 
1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3), comprising a sense strand and an antisense strand forming a duplex region,
wherein the antisense strand comprises at least 17 contiguous nucleotides which differ by no more than three nucleotides from nucleotides 1354-1395 of SEQ ID NO:1,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification,
wherein at least one of the nucleotide modifications is selected from the group consisting of a 2′-O-methyl nucleotide modification, a 2′-fluoro nucleotide modification, and a nucleotide comprising a 5′-phosphorothioate group modification, and
wherein a ligand comprising an N-acetylgalactosamine (GalNAc) is conjugated to at least one strand of the dsRNA agent.